Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06916897 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06916897 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT06916897, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purposes of this Phase 1 study of sevasemten are to: 1. Evaluate the effect of multiple-dose administration of verapamil on the single-dose of sevasemten in healthy adults 2. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without verapamil in healthy adult subjects. 3. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without food in healthy adult subjects.
Interventions
- DRUG Verapamil
- DRUG sevasemten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2025-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06916897
The ClinicalTrials.gov registry entry for NCT06916897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Verapamil is the first listed.
NCT06916897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06916897 about?
NCT06916897 is a clinical study titled "A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers". The purposes of this Phase 1 study of sevasemten are to: 1. Evaluate the effect of multiple-dose administration of verapamil on the single-dose of sevasemten in healthy adults 2. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without verapamil in healthy a...
What is the current status of trial NCT06916897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-01-08. Estimated completion is 2025-02-22.
What interventions are being tested in trial NCT06916897?
The interventions under investigation include: Verapamil (DRUG), sevasemten (DRUG).
Who is sponsoring clinical trial NCT06916897?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.